Atea Pharmaceuticals, Inc.
AVIR
$3.10
$0.010.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 38.23M | 2.42M | 3.44M | 21.91M | 20.29M |
| Gross Profit | -38.23M | -2.42M | -3.44M | -21.91M | -20.29M |
| SG&A Expenses | 7.22M | 9.07M | 9.46M | 13.36M | 11.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.45M | 41.42M | 39.04M | 35.27M | 31.34M |
| Operating Income | -45.45M | -41.42M | -39.04M | -35.27M | -31.34M |
| Income Before Tax | -41.85M | -36.95M | -34.07M | -33.32M | -30.93M |
| Income Tax Expenses | 196.00K | 207.00K | 203.00K | 225.00K | 226.00K |
| Earnings from Continuing Operations | -42.05M | -37.16M | -34.27M | -33.54M | -31.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.05M | -37.16M | -34.27M | -33.54M | -31.15M |
| EBIT | -45.45M | -41.42M | -39.04M | -35.27M | -31.34M |
| EBITDA | -45.35M | -41.32M | -38.94M | -35.16M | -31.23M |
| EPS Basic | -0.53 | -0.44 | -0.40 | -0.40 | -0.37 |
| Normalized Basic EPS | -0.33 | -0.28 | -0.25 | -0.22 | -0.19 |
| EPS Diluted | -0.53 | -0.44 | -0.40 | -0.40 | -0.37 |
| Normalized Diluted EPS | -0.33 | -0.28 | -0.25 | -0.22 | -0.19 |
| Average Basic Shares Outstanding | 79.05M | 83.75M | 85.16M | 84.46M | 84.42M |
| Average Diluted Shares Outstanding | 79.05M | 83.75M | 85.16M | 84.46M | 84.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |